All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy
Background and Aim Hepatitis C virus (HCV) cure with direct‐acting antiviral (DAA) therapy improves survival in patients with HCV‐related hepatocellular carcinoma (HCC). We hypothesized that HCV‐HCC survival has increased in the DAA era, more than other aetiologies of HCC. We aimed to evaluate survi...
Gespeichert in:
Veröffentlicht in: | Journal of gastroenterology and hepatology 2021-12, Vol.36 (12), p.3515-3523 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3523 |
---|---|
container_issue | 12 |
container_start_page | 3515 |
container_title | Journal of gastroenterology and hepatology |
container_volume | 36 |
creator | Lockart, Ian Hajarizadeh, Behzad Buckley, Niamh Davison, Scott Prakoso, Emilia Levy, Miriam T George, Jacob Dore, Gregory J Danta, Mark |
description | Background and Aim
Hepatitis C virus (HCV) cure with direct‐acting antiviral (DAA) therapy improves survival in patients with HCV‐related hepatocellular carcinoma (HCC). We hypothesized that HCV‐HCC survival has increased in the DAA era, more than other aetiologies of HCC. We aimed to evaluate survival following HCC diagnosis in the pre‐DAA and DAA eras, across each aetiology of HCC.
Methods
Patients with HCC at three tertiary referral hospitals were included retrospectively (January 2008 to December 2019). Patients were categorized as HCV‐HCC, hepatitis B virus (HBV)‐HCC, or non‐viral HCC. For each aetiology, the risk of death following incident HCC among patients diagnosed in the DAA era (2015–2019) was compared with patients diagnosed in the pre‐DAA era (2008–2014).
Results
Among 1161 patients, there were 422 (36%) patients with HCV‐HCC, 227 (20%) with HBV‐HCC, and 512 (44%) with non‐viral HCC. In adjusted analysis, the risk of death was lower in patients with HCV‐HCC diagnosed in 2015–2019, compared with patients diagnosed in 2008–2014 (adjusted hazard ratio [aHR]: 0.68; 95% confidence interval [CI]: 0.52–0.89; P = 0.005). In contrast, there was no difference in the risk of death between time periods for patients with HBV‐HCC (HR: 0.91; 95% CI: 0.64–1.29; P = 0.602) or non‐viral HCC on adjusted analysis (aHR: 0.92; 95% CI: 0.74–1.15; P = 0.476). Although patients with HBV‐HCC had better survival compared with patients with HCV‐HCC in 2008–2014 (aHR: 0.74; 95% CI: 0.55–0.98; P = 0.037), this difference disappeared in 2015–2019 (aHR: 1.26; 95% CI: 0.90–1.77; P = 0.175).
Conclusions
Hepatitis C virus‐related HCC survival has increased in the DAA era, whereas adjusted survival remained stable for HBV‐HCC and non‐viral HCC. |
doi_str_mv | 10.1111/jgh.15687 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2572529907</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2572529907</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-77017cf44e92c18b01e11235ae5dd5a9be9d85de183ba4d936ac86dbb9b009c13</originalsourceid><addsrcrecordid>eNp10L9u2zAQBnCiSFC7Toe-QEGgSzoo4UmiKI6Gkb8wkCUZA-JEnW0asuSSkgNvfYQ-Y56kdJ12KBAut_zuw_Fj7AuIC4jvcr1cXYAsSvWBjSHPRQIqL07YWJQgE52BHrFPIayFELlQ8iMbZblMhSjLMXueNs3rz18Wh0B8RVvsO0tNMzTouUVvXdttkIfB79wOG-5a3q-Ik0feLXjtPNk-rqPtXbvk2PZu53x0EXnc7s_Y6QKbQJ_f5oQ9XV89zm6T-cPN3Ww6T2wmM5UoJUDZRZ6TTi2UlQACSDOJJOtaoq5I16WsCcqswrzWWYG2LOqq0pUQ2kI2YefH3K3vfgwUerNx4fAPbKkbgkmlSmWqtVCRfvuPrrvBt_E6kxYAUkmhdFTfj8r6LgRPC7P1boN-b0CYQ-cmdm7-dB7t17fEodpQ_U_-LTmCyyN4cQ3t308y9ze3x8jfXKeNKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2611575079</pqid></control><display><type>article</type><title>All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Lockart, Ian ; Hajarizadeh, Behzad ; Buckley, Niamh ; Davison, Scott ; Prakoso, Emilia ; Levy, Miriam T ; George, Jacob ; Dore, Gregory J ; Danta, Mark</creator><creatorcontrib>Lockart, Ian ; Hajarizadeh, Behzad ; Buckley, Niamh ; Davison, Scott ; Prakoso, Emilia ; Levy, Miriam T ; George, Jacob ; Dore, Gregory J ; Danta, Mark</creatorcontrib><description>Background and Aim
Hepatitis C virus (HCV) cure with direct‐acting antiviral (DAA) therapy improves survival in patients with HCV‐related hepatocellular carcinoma (HCC). We hypothesized that HCV‐HCC survival has increased in the DAA era, more than other aetiologies of HCC. We aimed to evaluate survival following HCC diagnosis in the pre‐DAA and DAA eras, across each aetiology of HCC.
Methods
Patients with HCC at three tertiary referral hospitals were included retrospectively (January 2008 to December 2019). Patients were categorized as HCV‐HCC, hepatitis B virus (HBV)‐HCC, or non‐viral HCC. For each aetiology, the risk of death following incident HCC among patients diagnosed in the DAA era (2015–2019) was compared with patients diagnosed in the pre‐DAA era (2008–2014).
Results
Among 1161 patients, there were 422 (36%) patients with HCV‐HCC, 227 (20%) with HBV‐HCC, and 512 (44%) with non‐viral HCC. In adjusted analysis, the risk of death was lower in patients with HCV‐HCC diagnosed in 2015–2019, compared with patients diagnosed in 2008–2014 (adjusted hazard ratio [aHR]: 0.68; 95% confidence interval [CI]: 0.52–0.89; P = 0.005). In contrast, there was no difference in the risk of death between time periods for patients with HBV‐HCC (HR: 0.91; 95% CI: 0.64–1.29; P = 0.602) or non‐viral HCC on adjusted analysis (aHR: 0.92; 95% CI: 0.74–1.15; P = 0.476). Although patients with HBV‐HCC had better survival compared with patients with HCV‐HCC in 2008–2014 (aHR: 0.74; 95% CI: 0.55–0.98; P = 0.037), this difference disappeared in 2015–2019 (aHR: 1.26; 95% CI: 0.90–1.77; P = 0.175).
Conclusions
Hepatitis C virus‐related HCC survival has increased in the DAA era, whereas adjusted survival remained stable for HBV‐HCC and non‐viral HCC.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.15687</identifier><identifier>PMID: 34520088</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Antiviral agents ; Antiviral Agents - therapeutic use ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - virology ; Death ; Hepatitis B ; Hepatitis C ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatocellular carcinoma ; Humans ; Liver cancer ; Liver Neoplasms - mortality ; Liver Neoplasms - virology ; Patients ; Retrospective Studies ; Survival ; Survival Analysis ; Viruses</subject><ispartof>Journal of gastroenterology and hepatology, 2021-12, Vol.36 (12), p.3515-3523</ispartof><rights>2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-77017cf44e92c18b01e11235ae5dd5a9be9d85de183ba4d936ac86dbb9b009c13</citedby><cites>FETCH-LOGICAL-c3537-77017cf44e92c18b01e11235ae5dd5a9be9d85de183ba4d936ac86dbb9b009c13</cites><orcidid>0000-0003-3031-5655 ; 0000-0001-5551-6811</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.15687$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.15687$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34520088$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lockart, Ian</creatorcontrib><creatorcontrib>Hajarizadeh, Behzad</creatorcontrib><creatorcontrib>Buckley, Niamh</creatorcontrib><creatorcontrib>Davison, Scott</creatorcontrib><creatorcontrib>Prakoso, Emilia</creatorcontrib><creatorcontrib>Levy, Miriam T</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><creatorcontrib>Dore, Gregory J</creatorcontrib><creatorcontrib>Danta, Mark</creatorcontrib><title>All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background and Aim
Hepatitis C virus (HCV) cure with direct‐acting antiviral (DAA) therapy improves survival in patients with HCV‐related hepatocellular carcinoma (HCC). We hypothesized that HCV‐HCC survival has increased in the DAA era, more than other aetiologies of HCC. We aimed to evaluate survival following HCC diagnosis in the pre‐DAA and DAA eras, across each aetiology of HCC.
Methods
Patients with HCC at three tertiary referral hospitals were included retrospectively (January 2008 to December 2019). Patients were categorized as HCV‐HCC, hepatitis B virus (HBV)‐HCC, or non‐viral HCC. For each aetiology, the risk of death following incident HCC among patients diagnosed in the DAA era (2015–2019) was compared with patients diagnosed in the pre‐DAA era (2008–2014).
Results
Among 1161 patients, there were 422 (36%) patients with HCV‐HCC, 227 (20%) with HBV‐HCC, and 512 (44%) with non‐viral HCC. In adjusted analysis, the risk of death was lower in patients with HCV‐HCC diagnosed in 2015–2019, compared with patients diagnosed in 2008–2014 (adjusted hazard ratio [aHR]: 0.68; 95% confidence interval [CI]: 0.52–0.89; P = 0.005). In contrast, there was no difference in the risk of death between time periods for patients with HBV‐HCC (HR: 0.91; 95% CI: 0.64–1.29; P = 0.602) or non‐viral HCC on adjusted analysis (aHR: 0.92; 95% CI: 0.74–1.15; P = 0.476). Although patients with HBV‐HCC had better survival compared with patients with HCV‐HCC in 2008–2014 (aHR: 0.74; 95% CI: 0.55–0.98; P = 0.037), this difference disappeared in 2015–2019 (aHR: 1.26; 95% CI: 0.90–1.77; P = 0.175).
Conclusions
Hepatitis C virus‐related HCC survival has increased in the DAA era, whereas adjusted survival remained stable for HBV‐HCC and non‐viral HCC.</description><subject>Antiviral agents</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - virology</subject><subject>Death</subject><subject>Hepatitis B</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - virology</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Viruses</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L9u2zAQBnCiSFC7Toe-QEGgSzoo4UmiKI6Gkb8wkCUZA-JEnW0asuSSkgNvfYQ-Y56kdJ12KBAut_zuw_Fj7AuIC4jvcr1cXYAsSvWBjSHPRQIqL07YWJQgE52BHrFPIayFELlQ8iMbZblMhSjLMXueNs3rz18Wh0B8RVvsO0tNMzTouUVvXdttkIfB79wOG-5a3q-Ik0feLXjtPNk-rqPtXbvk2PZu53x0EXnc7s_Y6QKbQJ_f5oQ9XV89zm6T-cPN3Ww6T2wmM5UoJUDZRZ6TTi2UlQACSDOJJOtaoq5I16WsCcqswrzWWYG2LOqq0pUQ2kI2YefH3K3vfgwUerNx4fAPbKkbgkmlSmWqtVCRfvuPrrvBt_E6kxYAUkmhdFTfj8r6LgRPC7P1boN-b0CYQ-cmdm7-dB7t17fEodpQ_U_-LTmCyyN4cQ3t308y9ze3x8jfXKeNKg</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Lockart, Ian</creator><creator>Hajarizadeh, Behzad</creator><creator>Buckley, Niamh</creator><creator>Davison, Scott</creator><creator>Prakoso, Emilia</creator><creator>Levy, Miriam T</creator><creator>George, Jacob</creator><creator>Dore, Gregory J</creator><creator>Danta, Mark</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3031-5655</orcidid><orcidid>https://orcid.org/0000-0001-5551-6811</orcidid></search><sort><creationdate>202112</creationdate><title>All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy</title><author>Lockart, Ian ; Hajarizadeh, Behzad ; Buckley, Niamh ; Davison, Scott ; Prakoso, Emilia ; Levy, Miriam T ; George, Jacob ; Dore, Gregory J ; Danta, Mark</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-77017cf44e92c18b01e11235ae5dd5a9be9d85de183ba4d936ac86dbb9b009c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antiviral agents</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - virology</topic><topic>Death</topic><topic>Hepatitis B</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - virology</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lockart, Ian</creatorcontrib><creatorcontrib>Hajarizadeh, Behzad</creatorcontrib><creatorcontrib>Buckley, Niamh</creatorcontrib><creatorcontrib>Davison, Scott</creatorcontrib><creatorcontrib>Prakoso, Emilia</creatorcontrib><creatorcontrib>Levy, Miriam T</creatorcontrib><creatorcontrib>George, Jacob</creatorcontrib><creatorcontrib>Dore, Gregory J</creatorcontrib><creatorcontrib>Danta, Mark</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lockart, Ian</au><au>Hajarizadeh, Behzad</au><au>Buckley, Niamh</au><au>Davison, Scott</au><au>Prakoso, Emilia</au><au>Levy, Miriam T</au><au>George, Jacob</au><au>Dore, Gregory J</au><au>Danta, Mark</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2021-12</date><risdate>2021</risdate><volume>36</volume><issue>12</issue><spage>3515</spage><epage>3523</epage><pages>3515-3523</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background and Aim
Hepatitis C virus (HCV) cure with direct‐acting antiviral (DAA) therapy improves survival in patients with HCV‐related hepatocellular carcinoma (HCC). We hypothesized that HCV‐HCC survival has increased in the DAA era, more than other aetiologies of HCC. We aimed to evaluate survival following HCC diagnosis in the pre‐DAA and DAA eras, across each aetiology of HCC.
Methods
Patients with HCC at three tertiary referral hospitals were included retrospectively (January 2008 to December 2019). Patients were categorized as HCV‐HCC, hepatitis B virus (HBV)‐HCC, or non‐viral HCC. For each aetiology, the risk of death following incident HCC among patients diagnosed in the DAA era (2015–2019) was compared with patients diagnosed in the pre‐DAA era (2008–2014).
Results
Among 1161 patients, there were 422 (36%) patients with HCV‐HCC, 227 (20%) with HBV‐HCC, and 512 (44%) with non‐viral HCC. In adjusted analysis, the risk of death was lower in patients with HCV‐HCC diagnosed in 2015–2019, compared with patients diagnosed in 2008–2014 (adjusted hazard ratio [aHR]: 0.68; 95% confidence interval [CI]: 0.52–0.89; P = 0.005). In contrast, there was no difference in the risk of death between time periods for patients with HBV‐HCC (HR: 0.91; 95% CI: 0.64–1.29; P = 0.602) or non‐viral HCC on adjusted analysis (aHR: 0.92; 95% CI: 0.74–1.15; P = 0.476). Although patients with HBV‐HCC had better survival compared with patients with HCV‐HCC in 2008–2014 (aHR: 0.74; 95% CI: 0.55–0.98; P = 0.037), this difference disappeared in 2015–2019 (aHR: 1.26; 95% CI: 0.90–1.77; P = 0.175).
Conclusions
Hepatitis C virus‐related HCC survival has increased in the DAA era, whereas adjusted survival remained stable for HBV‐HCC and non‐viral HCC.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34520088</pmid><doi>10.1111/jgh.15687</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3031-5655</orcidid><orcidid>https://orcid.org/0000-0001-5551-6811</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0815-9319 |
ispartof | Journal of gastroenterology and hepatology, 2021-12, Vol.36 (12), p.3515-3523 |
issn | 0815-9319 1440-1746 |
language | eng |
recordid | cdi_proquest_miscellaneous_2572529907 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Antiviral agents Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - virology Death Hepatitis B Hepatitis C Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatocellular carcinoma Humans Liver cancer Liver Neoplasms - mortality Liver Neoplasms - virology Patients Retrospective Studies Survival Survival Analysis Viruses |
title | All‐cause hepatocellular carcinoma survival in the era of direct‐acting antiviral therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A36%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=All%E2%80%90cause%20hepatocellular%20carcinoma%20survival%20in%20the%20era%20of%20direct%E2%80%90acting%20antiviral%20therapy&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Lockart,%20Ian&rft.date=2021-12&rft.volume=36&rft.issue=12&rft.spage=3515&rft.epage=3523&rft.pages=3515-3523&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.15687&rft_dat=%3Cproquest_cross%3E2572529907%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2611575079&rft_id=info:pmid/34520088&rfr_iscdi=true |